A long-acting version of popular diabetes drug Byetta has been found to be superior in controlling blood glucose and losing weight to two other well used diabetes medications .
The once-weekly drug is being developed jointly by Eli Lilly and Co and Amylin Pharmaceuticals . The next stage for the diabetes drug is to seek regulatory approval from the Food and Drug Administration. Current versions of Byetta are injected twice daily.
Lazard Capital Markets analyst Matthew Osborne reportedly commented: “Today’s data confirm the superiority of exenatide LAR, which has only been assumed to this date, but not tested head- to-head versus existing oral therapies. We believe data from DURATION-3 trial comparing exenatide LAR versus Lantus could show similar superiority, or at least similar A1C, but with greater weight loss .”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…